Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Capital Expenditures (2017 - 2025)

Aclaris Therapeutics has reported Capital Expenditures over the past 9 years, most recently at -$66000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at -$66000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $21000.0 (down 82.64% YoY), and the annual figure for FY2025 was $21000.0, down 82.64%.
  • Capital Expenditures for Q4 2025 was -$66000.0 at Aclaris Therapeutics, down from $23000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for ACRS hit a ceiling of $933000.0 in Q4 2023 and a floor of -$408000.0 in Q3 2023.
  • Median Capital Expenditures over the past 5 years was $103000.0 (2021), compared with a mean of $145437.5.
  • Biggest five-year swings in Capital Expenditures: soared 2400.0% in 2021 and later tumbled 587.32% in 2022.
  • Aclaris Therapeutics' Capital Expenditures stood at $200000.0 in 2021, then surged by 200.5% to $601000.0 in 2022, then soared by 55.24% to $933000.0 in 2023, then tumbled by 101.5% to -$14000.0 in 2024, then crashed by 371.43% to -$66000.0 in 2025.
  • The last three reported values for Capital Expenditures were -$66000.0 (Q4 2025), $23000.0 (Q3 2025), and $21000.0 (Q2 2025) per Business Quant data.